Science and Technology

Author Archive | Michael Pohl

April 1, 2021

Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement

Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks WARMINSTER, PA, WALTHAM, MA, MUNICH, GERMANY, April 1, 2021 — Arbutus Biopharma Corporation (NASDAQ: ABUS), X-Chem, Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced today that they have entered […]

Continue Reading
February 2, 2021

X-Chem Enters into Multitarget Oncology Discovery Research Collaboration and License Agreement with Genentech

 Collaboration Includes Licensing of Preclinical Small Molecule Program  WALTHAM, Mass.; Feb. 2, 2021 (Business Wire) – X-Chem, Inc., a global leader in DNA-Encoded Library (DEL) technology to identify novel drug leads, announced today that it has entered into a research collaboration and license agreement with Genentech, a member of the Roche Group. The goal of […]

Continue Reading
January 26, 2021

X-Chem acquires IntelliSyn and sister company, AviSyn, to extend and streamline drug discovery service range

Acquisition allows X-Chem to offer a more comprehensive, integrated, screen-to-lead drug discovery process to pharma and biotech clients IntelliSyn’s Founder and CEO Jeffrey Albert to join X-Chem management team Waltham, Mass., US: Jan. 26, 2021 (Business Wire) – X-Chem, Inc. (X-Chem), the industry-leading provider of DNA-Encoded Library (DEL)-based discovery services, has acquired IntelliSyn, a Montreal-based […]

Continue Reading
January 6, 2021

Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases

Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases Paris and Waltham, Mass.; Jan. 6, 2021 (Business Wire) – Servier, a global pharmaceutical Group and X-Chem, Inc., a privately held drug discovery company announced today a partnership to identify and develop novel small molecules for the treatment of neurological disorders. Under the terms of […]

Continue Reading